Cutler Group LP Voyager Therapeutics, Inc. Transaction History

Cutler Group LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 25, 2022	SELL	$5.57 - $7.47 $17,656 - $23,679	-3,170 Reduced 55.58%	2,534 $15,000
Q2 2022 Aug 04, 2022	BUY	$4.82 - $10.09 $12,560 - $26,294	2,606 Added 84.12%	5,704 $33,000
Q1 2022 Apr 14, 2022	BUY	$2.75 - $9.44 $8,519 - $29,245	3,098 New	3,098 $23,000
Q1 2020 May 07, 2020	SELL	$6.8 - $14.66 $3,400 - $7,330	-500 Closed	0 $0
Q4 2019 Feb 06, 2020	BUY	$12.82 - $16.85 $1,282 - $1,685	100 Added 25.0%	500 $6,000
Q3 2019 Oct 28, 2019	BUY	$16.31 - $28.29 $4,893 - $8,487	300 Added 300.0%	400 $6,000
Q4 2017 Jan 17, 2018	SELL	$12.26 - $25.88 $1,226 - $2,588	-100 Reduced 50.0%	100 $1,000
Q3 2017 Oct 17, 2017	BUY	$8.37 - $20.59 $1,673 - $4,118	200	200 $4,000

130

34.7M

39.7K

34.6K

Ticker VYGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,647,600
Market Cap $219M
Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.